君實生物(01877.HK)調整2020年限制性股票激勵計劃首次授予激勵對象名單及數量
格隆匯 11 月 17日丨君實生物(01877.HK)發佈公告,71名激勵對象因離職失去激勵資格或因其他原因自願放棄激勵資格,公司董事會根據股東大會的授權,對本激勵計劃首次授予激勵對象人數及擬授予數量進行調整。本次調整後,本激勵計劃首次授予人數由2,004人調整為1,933人,首次授予限制性股票數量由2,858.95萬股調整為2,851.90萬股,預留部分數量由714.70萬股調整為712.90萬股,限制性股票授予總數由3,573.65萬股調整為3,564.80萬股。
公告表示,公司本次對本激勵計劃授予激勵對象名單和授予數量的調整不會對公司的財務狀況和經營成果產生實質性影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.